Business
Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®
SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening
About this update from Aethlon Medical, Inc.
[{"type":"text","content":"SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced the publication of a manuscript in the peer-reviewed journal Frontiers in Medicine describing two cases of critically ill COVID-19 patients treated with the Hemopurifier®, Aethlon's therapeutic blood filtration system. The publication, titled \"Removal of COVID-19 spike protein, whole virus, exosomes and exosomal microRNAs by the Hemopurifier® lectin-affinity cartridge in critically Ill patients with COVID-19 infection,\" is available here: https://www.frontiersin.org/articles/10.3389/fmed.2021.744141/full\n\n The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions. These two patient case studies are notable because they are the first descriptions of the Hemopurifier® successfully removing exosomes, exosomal microRNAs, and SARS-CoV-2 virus in patients with COVID-19. In the first patient, exosome and exosomal microRNA removal was associated with improved coagulopathy, oxygenation, and clinical recovery. In the second patient, SARS-CoV-2 virus removal by the Hemopurifier® was demonstrated, but the patient expired because the disease was advanced and had triggered multiple organ system failures. The patient had completed Hemopurifier® treatment and passed away while receiving Continuous Renal Replacement Therapy (CRRT). Hemopurifier® treatment sessions were well tolerated by both patients without side effects.\n\n \"The emergence of COVID-19 variants has prompted an even greater need for innovative COVID-19 treatments. These results demonstrate that the Hemopurifier® can remove exosomes and viral particles related to COVID-19 from the blood stream in humans,\" said Charles J. Fisher, Jr., M.D., CEO of Aethlon Medical and an author of the manuscript. \"We remain optimistic about our ongoing studies of the Hemopurifier® as a treatment for critical COVID-19 patients.\"\n\n The safety and feasibility of the Aethlon Hemopurifier® is being evaluated in an active Early Feasibility Study, analogous to a Phase 1 clinical trial for a drug or biologic, that is designed to enroll up to 40 COVID-19 ICU patients [NCT04595903].\n\n \n About Aethlon and the Hemopurifier®\n \n...